Collectively, these findings identified the Prickle4‐mediated microenvironmental remodeling as the key resistance mechanism to PARPi, and support the therapeutic promise of multimodal therapy combining PARPi with anti‐angiogenic agents for glioma treatment. This evidence concerns the gene PRICKLE4 and glioma.